- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01926730
Food and Crohn's Exacerbation Study (FACES) (FACES)
February 13, 2017 updated by: University of Pennsylvania
The proposed study is a randomized controlled trial of a limited restriction diet compared to a regular diet among patients with Crohn's disease (CD) in remission.
At baseline, patients will complete a semi-quantitative food frequency questionnaire assessing usual dietary patterns over the preceding month.
Disease activity will be assessed with the abbreviated Crohn's Disease Activity Index (aCDAI)59.
Self-reported disease status will be assessed during follow-up using an internet-based questionnaire.
Repeat assessment of adherence to the study diets will be assessed with food frequency questionnaires (FFQs) administered after 20 weeks.
Follow-up duration will be for 48 weeks.
Statistical analysis will compare the time to relapse using Cox regression for patients in the two study arms.
In the exploratory aim, we will compare outcomes among patients in the highest tertile for other food items and nutrients to those in the lowest tertile based on self-reported usual dietary patterns at baseline.
Thus, the study population will be analyzed both as a randomized controlled trial and as a prospective cohort study.
Study Overview
Study Type
Interventional
Enrollment (Actual)
216
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have an established diagnosis of CD.
- All patients must be in clinical remission at the time of entry into the study. Remission is defined as an aCDAI of less than 150.
Exclusion Criteria:
Inflammatory bowel disease (IBD) unspecified / Indeterminate colitis
Total or sub-total colectomy, ileostomy, or colostomy
Unable to read and speak English
No internet access
Steroids other than budesonide ≤6mg/day with the prior two weeks
Perianal fistula or abscess with more than scant drainage
Age less than 18 years
Pregnant or breastfeeding women
Unwilling to follow the study diet
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Usual diet
Patients will follow a usual diet and consume at least 16 oz of water per day
|
|
|
Experimental: Restriction diet
Participants will follow a diet that limits intake of selected food items.
Patients will consume at least 16 oz of water per day.
|
Selected food items will be limited in the participants diet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relapse of Crohn's Disease (CD)
Time Frame: Every 8 weeks during the 48 week study period
|
Relapse of CD is defined as an increase in the aCDAI by >=60 points and to >150.
Additionally, undergoing CD surgery or starting any new CD medication (steroids, mesalamine, azathioprine, methotrexate, anti-Tumor Necrosis Factor α (anti-TNF), anti-α4) for the treatment of CD symptoms during the interval between two visits will be considered to have identified a clinical relapse.
|
Every 8 weeks during the 48 week study period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2013
Primary Completion (Actual)
June 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
August 18, 2013
First Submitted That Met QC Criteria
August 18, 2013
First Posted (Estimate)
August 21, 2013
Study Record Updates
Last Update Posted (Actual)
February 14, 2017
Last Update Submitted That Met QC Criteria
February 13, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K24-DK078228-FACES
- K24DK078228 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn's Disease
-
ProgenaBiomeWithdrawnCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingCrohn's Disease Aggravated | Crohn's Disease in Remission
-
Massachusetts General HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American...RecruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's EsophagitisUnited States
-
Tanabe Pharma CorporationCompleted
-
Massachusetts General HospitalRecruitingCrohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Inflammatory Bowel Disease (IBD) | Crohn's Colitis | Indeterminate Colitis | Ulcerative Colitis (UC) | Ulcerative Proctitis | Ulcerative Proctosigmoiditis | Crohn's Disease Colon | IBD-unclassified (IBD-U)United States
-
Richard Burt, MDTerminatedCROHN'S DISEASEUnited States
-
Kate Farms IncUniversity of MinnesotaCompleted
-
Agomab Spain S.L.U.Active, not recruitingFibrostenotic Crohn's DiseaseUnited States, Spain, Denmark, Austria, Poland, Italy, Canada, Germany
-
AbbVieCompletedCrohn's Disease (CD)United States, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Romania, Spain, United Kingdom, Poland, Slovakia, Belgium
Clinical Trials on Restriction diet
-
Cairo UniversityRecruitingObstructive Sleep Apnea | Tinnitus, SubjectiveEgypt
-
University Hospital of North NorwayNordlandssykehuset HFCompletedIrritable Bowel Syndrome | Fructose MalabsorptionNorway
-
Chin HsuCompleted
-
Guangzhou Sport UniversityUnknownChildhood Obesity | Adolescent ObesityChina
-
Clinica Universidad de Navarra, Universidad de...Recruiting
-
University of JordanCompletedThe Effect of Ketogenic-caloric Restricted Diet on Metabolic Endotoxemia in Prediabetic Obese AdultsObesity | Insulin Resistance | Prediabetes | Ketogenic Diet | Caloric Restriction | Metabolic Endotoxemia | Inflammation BiomarkersJordan
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedObesity | Obstructive Sleep ApneaBrazil
-
Cairo UniversityRecruiting
-
Wake Forest University Health SciencesNational Institute on Aging (NIA)CompletedMetabolic Syndrome | Abdominal ObesityUnited States